FIELD: biotechnology.
SUBSTANCE: method is characterised in that the DNA of the structure RNAb indicated on Figure 1, which encodes the fused protein of three parts, where N-terminal position is green fluorescent protein GFP, central - peptide of 73 amino acid residues with the amino acid sequence of SRKKCNFATTPICEYDGNMVSGYKKVMATIDSFQAFNTSYIHYTDEQIEW KDPDGMLKDHLNILVTKDIDFDT, and C-terminal - light chain of double-stranded protein Kunitz-type inhibitor from potato tubers (PKPI-BI), are introduced into cells of E. coli. The cells transformed by this construction are cultured, the biomass is lysed, the insoluble fraction of the lysate is separated by centrifugation. The product of expression in the form of inclusion bodies is solubilised with the denaturant. Chromatography is carried out under denaturing conditions. The resulting product is used for detection of specific antibodies in serum of patients with hemorrhagic fever with renal syndrome.
EFFECT: invention enables to obtain the recombinant antigen G2 of Hantavirus Dobrava with increased yield.
6 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF OBTAINING RECOMBINANT ANTIGEN G2 OF DOBRAVA HANTAVIRUS IN E.coli CELLS | 2012 |
|
RU2509805C2 |
| METHOD OF OBTAINING RECOMBINANT ENZYME-LABELLED ANTIGEN G2 OF HANTAVIRUS IN E. coli CELLS AIMED AT ITS APPLICATION IN IMMUNOSORBENT ASSAY IN HFRS DIAGNOSTICS | 2012 |
|
RU2539836C2 |
| pET21-GST-CD RECOMBINANT PLASMID WHICH ENSURES SYNTHESIS AND SECRETION OF Gn ECTODOMAIN OF HANTAAN VIRUS GLYCOPROTEIN, AND BL21(DE3)PLYSE pET21-GST-CD RECOMBINANT ESCHERICHIA COLI STRAIN, PRODUCER OF Gn PROTEIN, ECTODOMAIN OF HANTAAN VIRUS GLYCOPROTEIN | 2023 |
|
RU2809199C1 |
| RECOMBINANT PLASMID pET21-GST-CD WHICH ENSURES THE SYNTHESIS AND SECRETION OF Gc ECTODOMAIN OF HANTAAN VIRUS GLYCOPROTEIN, AND THE RECOMBINANT ESCHERICHIA COLI STRAIN BL21(DE3)pLysE pET21-GST-CD, A PRODUCER OF THE Gc PROTEIN, THE ECTODOMAIN OF HANTAAN VIRUS GLYCOPROTEIN | 2023 |
|
RU2807520C1 |
| METHOD FOR PRODUCING "HANTA-N" TEST SYSTEM FOR DETERMINING SPECIFIC ACTIVITY OF VACCINE AGAINST HEMORRHAGIC FEVER WITH RENAL SYNDROME | 2012 |
|
RU2590606C2 |
| METHOD OF OBTAINING IMMUNOENZYMATIC TEST SYSTEM FOR DETERMINATION OF EPITOPES OF ENVELOPE PROTEIN OF PUUMALA VIRUS WITH PROTECTIVE ORIENTATION IN VACCINE PREPARATIONS AGAINST HAEMORRHAGIC FEVER WITH RENAL SYNDROME | 2013 |
|
RU2565543C2 |
| METHOD FOR PREPARING COMBINED BIVALENT, TISSUE-CULTURE, INACTIVATED, CONCENTRATED, PURIFIED VACCINE FOR PREVENTING HEMORRHAGIC FEVER AND RENAL SYNDROME | 2009 |
|
RU2445117C2 |
| HEMORRHAGIC FEVER AND RENAL SYNDROME CAUSAL VIRUS STRAIN FOR PREPARING VACCINE PREPARATIONS (VERSIONS) | 2009 |
|
RU2423520C1 |
| METHOD FOR PRODUCING CULTURAL, POLYVALENT EPIDEMIC HAEMORRHAGIC FEVER DIAGNOSTICUM FOR INDIRECT IMMUNOFLUORESCENCE | 2010 |
|
RU2431148C1 |
| VIRUS STRAIN FOR PRODUCING VACCINE DRUGS AGAINST HEMORRHAGIC FEVER WITH RENAL SYNDROME (OPTIONS) | 2018 |
|
RU2683508C1 |
